spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Abraxis BioScience 

 HSMN NewsFeed - 17 Nov 2020
Celularity Announces Appointments of Chief Medical Officer and Senior Vice President of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2020
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Nov 2016
Marina Biotech Announces Merger with IthenaPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Mar 2016
Allergan Confirms Generic Abraxane(R) Patent Challenge
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 15 Oct 2015
Biothera Appoints Dr. Jose Iglesias as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Feb 2014
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Apr 2013
BIND Therapeutics Appoints Gregory I. Berk, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Oct 2010
Celgene Completes Acquisition of Abraxis
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Jul 2010
Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jul 2010
ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Jun 2010
Celgene to Acquire Abraxis BioScience Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2010
Tesaro, Inc. Secures $60 Million in Start-up Funding
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2010
SurModics Announces Organizational and Leadership Changes
Devices Personnel
 HSMN NewsFeed - 28 Jan 2010
Abraxis BioScience Confirms Plan to Spin-off Abraxis Health in 2010 and Announces Management Structure
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Nov 2009
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jul 2009
Abraxis BioScience Names Mary Lynne Hedley, Ph.D., Executive Vice President of Operations and Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jul 2009
Abraxis BioScience Appoints Rick Rodgers Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2009
Marty J. Duvall Joins Abraxis BioScience as Senior Vice President, Global Marketing and International Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Apr 2009
Abraxis BioScience Names Lonnie Moulder President and Chief Executive Officer; Soon-Shiong Remains Executive Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Feb 2009
Abraxis BioScience Launches ABRAXANE in Germany
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2008
Abraxis BioScience and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in Australia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jul 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Jun 2008
ABRAXANE(R) in Combination with Trastuzumab and Carboplatin Evaluated as First-Line Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
Combination Therapy of Solvent-Free ABRAXANE(R) and the Targeted Therapy Bevacizumab Evaluated as First-Line Treatment for Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2008
"The Group Room(R)" to Broadcast 10th Anniversary Show From the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), Sunday, June 1
Oncology
 HSMN NewsFeed - 30 Apr 2008
APP Pharmaceuticals Names Thomas H. Silberg Chief Executive Officer; Appoints Richard J. Tajak Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2008
Abraxis BioScience Reports Promising Clinical Data in Advanced Pancreatic Cancer Using a Combination of nab-Paclitaxel (ABRAXANE(R)) and Gemcitabine (Gemzar(R))
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Mar 2008
Acusphere Licenses Hydrophobic Drug Delivery System to Cephalon for $10 Million
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 17 Mar 2008
Abraxis Bioscience Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Feb 2008
APP Pharmaceuticals Receives Final Approval for Irinotecan Hydrochloride Injection
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 8 Feb 2008
APP Pharmaceuticals Receives FDA Approval for Bleomycin Sulfate for Injection, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 8 Feb 2008
APP Pharmaceuticals Receives FDA Approval for Caffeine Citrate Oral Solution, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 7 Feb 2008
Abraxis Bioscience Establishes Global Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2008
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Jan 2008
APP Pharmaceuticals Receives FDA Approval for Polymyxin B Sulfate for Injection, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 3 Dec 2007
Cenomed BioSciences Announces Licensing Agreement with ThioPharma, Inc.
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 8 Nov 2007
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
Abraxis BioScience Announces the Closing Date for the Separation of Its Proprietary Business from Its Hospital-Based Business
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2007
Acusphere to Develop Potential Abraxane(R) Bioequivalent
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 18 Oct 2007
Abraxis BioScience Receives a Positive Opinion in Europe from the CHMP for the Approval of ABRAXANE for the Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Oct 2007
Abraxis BioScience and Biocon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Oct 2007
Abraxis Bioscience Reaches Agreement with the FDA Following Special Protocol Assessment for Phase III Trial of ABRAXANE in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2007
APP Receives Tentative FDA Approval for Irinotecan Hydrochloride Injection, 20 mg/mL Packaged in 2 mL and 5 mL Single-Use Vials
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 21 Aug 2007
Abraxis BioScience and The Scripps Research Institute Enter Exclusive Licensing Agreement for the Worldwide Development and Commercialization of a Novel Epothilone Therapeutic for the Treatment of Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 10 Aug 2007
APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 8 Aug 2007
Abraxis BioScience Announces Licensing Agreement with Biocon Limited for the Commercialization of ABRAXANE in India
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 Aug 2007
Abraxis BioScience Receives FDA Approval for Oxytocin Injection 10 USP Units/mL in a 30 mL Vial
Biopharmaceuticals Distribution
 HSMN NewsFeed - 6 Aug 2007
Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 19 Jul 2007
Abraxis BioScience and Biocon Limited Announce Licensing Agreement for G-CSF in North America and the European Union
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Jul 2007
Spectrum Strengthens Management With the Appointment of George Uy, an Industry Veteran, as Vice President, Marketing Oncology/Urology
Biopharmaceuticals Oncology Urology Personnel
 HSMN NewsFeed - 4 Jul 2007
Circassia Announces the Appointment of Sir Richard Sykes as Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jun 2007
Abraxis BioScience Exclusively Licenses Intellectual Property Portfolio Designed to Personalize Treatment for Colorectal Cancer from the University of Southern California
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 4 Jun 2007
New Data Shows Promising Antitumor Activity with nab-paclitaxel (ABRAXANE(R)) in Combination and as a Single Agent for the Treatment of Lung and Ovarian Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Presented at ASCO
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 29 May 2007
"The Group Room(R)" to Broadcast 10th Anniversary Show From the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), Sunday, June 3
Oncology
 HSMN NewsFeed - 10 May 2007
Abraxis BioScience Receives FDA Approvals for Clindamycin Injection, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 7 May 2007
Abraxis BioScience Announces Joint Venture With Cenomed for the Development of Novel Therapeutics for Neurological Diseases
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Apr 2007
Abraxis BioScience Receives FDA Tentative Approval for Fosphenytoin Sodium Injection, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 20 Feb 2007
Cobalis Appoints Three Pharmaceutical Industry Executives to Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2007
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Dec 2006
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2006
Abraxis BioScience Receives FDA Approval for Ampicillin and Sulbactam for Injection, 15g, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 28 Sep 2006
Abraxis BioScience Files Marketing Application with the European Medicines Agency for ABRAXANE in the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Sep 2006
Abraxis BioScience Names Leadership Team for Its Abraxis Pharmaceutical Products Division
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Sep 2006
Abraxis Oncology Appoints Vice President Global Drug Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jun 2006
Abraxis BioScience Completes Acquisition of the AstraZeneca U.S. Branded Anesthetic and Analgesic Product Lines
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 25 May 2006
Abraxis BioScience Appoints New Officers to Executive Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 May 2006
Abraxis BioScience Bolsters Manufacturing and Global Operational Expertise With Key Senior Executives
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 14

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 14 additional stories matching:
Abraxis BioScience
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.